ZoeNCure Therapeutics Raises INR 20 Crore and Licenses Antibody Platform for Liver Cancer ADCs
ZoeNCure Therapeutics, an Indian oncology biotech firm, secured INR 20 Crore in a Seed funding round led by the Tyagi Family to advance its antibody-drug conjugate (ADC) program targeting liver and gastrointestinal cancers. The company also licensed novel antibody technology from Styx Biotechnologies to develop dual-payload ADCs aimed at hepatocellular carcinoma. The funds will support preclinical studies, manufacturing scale-up, and regulatory submissions for upcoming Phase 1 clinical trials in India.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 39/100.
Outlets measured: thehindu, thehindu, thetribune, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 3 Sept, 11:49 am. Other outlets followed.